Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation

King’s College London Scientists Develop New Alzheimer’s Therapy Targeting DNA Repair and Inflammation

Researchers at King’s College London have identified a promising new strategy for combating Alzheimer’s disease that addresses multiple debilitating effects simultaneously. The study indicates that an experimental drug, originally developed for spinal cord injuries, may facilitate the repair of damaged DNA, curtail inflammation, and target critical biological alterations linked to the condition.

The drug, known as KCL-286, has shown encouraging results in a mouse model of Alzheimer’s disease. Unlike therapies that primarily target toxic protein accumulation in the brain, this approach addresses additional processes that may initiate long before the disease reaches its advanced stages.

A notable advantage is that KCL-286 has already completed Phase 1 human safety and tolerability trials. This development could significantly shorten the timeline required for further clinical testing, although its efficacy against Alzheimer’s in humans remains unestablished.

“KCL-286 is a first-in-class, orally bioavailable small molecule that successfully completed Phase 1 human safety and tolerability trials. This milestone will dramatically reduce the traditional multi-year timeline required for new drug development,” stated Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology & Neuroscience, King’s College London.

This small molecule can be administered orally, offering a potential convenience over treatments requiring injections or infusions.

Why Alzheimer’s Disease Is So Difficult to Treat

Alzheimer’s disease involves a complex series of brain changes, making effective treatments particularly challenging. Its two most recognized features are the abnormal accumulation of amyloid-beta and tau proteins. Amyloid-beta forms sticky deposits between nerve cells, while abnormal tau proteins create intracellular tangles. These alterations interfere with normal brain function and are associated with progressive neuronal loss.

Much of the effort has focused on these two proteins—where amyloid-beta clumps and tau forms tangles—though traditional therapies have only demonstrated modest benefits. Researchers are increasingly investigating other contributors, including DNA damage and neural inflammation, which often appear early in the disease course. KCL-286’s breakthrough shows promise by targeting multiple pathways, including DNA repair and inflammation, rather than relying solely on amyloid or tau clearance.

How Vitamin A Pathways Could Help Fight Alzheimer’s

The mechanism of action lies in the retinoic acid pathway, a biological system linked to the body’s processing and utilization of vitamin A.

Earlier research indicated that disruptions in this pathway were associated with the formation of amyloid-beta deposits in rats, a hallmark of Alzheimer’s. KCL-286 activates a specific protein within this system to regulate essential biological processes. Its ability to repair DNA double-strand breaks was previously demonstrated in neuropathic pain research, leading scientists to investigate if the same mechanism could address DNA damage from Alzheimer’s.

Repairing a Dangerous Type of DNA Damage

DNA contains the genetic instructions necessary for cellular function, but some forms of damage are critical. One particularly serious type is the double-strand break, where both strands of the DNA molecule are severed, disrupting normal cellular activity and threatening cell survival.

KCL-286 promotes the repair of these breaks, representing a key new feature of Alzheimer’s treatment.

The researchers identified molecular pathways shared by acute spinal cord injury and Alzheimer’s disease. Because these conditions involve overlapping biological mechanisms, the team believed a drug developed for spinal cord injury might also improve certain Alzheimer’s-related changes in neurons.

Their findings support this possibility, showing that KCL-286 can influence several cellular pathways involved in the disease.

A Promising New Direction for Alzheimer’s Treatment

The results highlight a shift in Alzheimer’s research: instead of concentrating on a single hallmark, scientists are exploring treatments that address interconnected causes of brain damage. KCL-286 is particularly interesting as it targets both DNA damage and inflammation—processes that can emerge early in the disease course—and has already successfully cleared Phase 1 human safety trials, potentially shortening the development timeline compared to entirely new candidates.

However, the findings remain preclinical. Additional studies and human clinical trials are necessary to determine if the drug can safely slow disease progression or improve patient outcomes.

Natasha Hill, one of the first authors on the paper, noted: “To develop an effective treatment for Alzheimer’s disease, we need to tackle multiple aspects of the disease. KCL-286 was able to target multiple disease-relevant cellular pathways, some of which are initiated very early in the disease course.”

Source link